JMT601 / CSPC Pharma - LARVOL DELTA

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy (clinicaltrials.gov) - P2 | N=156 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P2 trial • Glomerulonephritis • Renal Disease

First-in-human trial of JMT601, a bispecific fusion protein targeting CD47 and CD20, in patients with relapse/refractory CD20 positive B-cell non-Hodgkin lymphoma (AACR 2025) - P1 | "27 patients (75.0%) were refractory to prior rituximab-based combination therapy. JMT601 had an encouraging anti-tumor effect in relapse/refractory CD20 positive B-cell NHL patients with acceptable safety profiles. This trial is registered at ClinicalTrials.gov (NCT06725524)."

Clinical • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • SIRPA

Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov) - P1/2 | N=7 | Terminated | Sponsor: Conjupro Biotherapeutics, Inc. | Suspended ➔ Terminated; Business reasons

Trial termination • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov) - P1/2 | N=7 | Suspended | Sponsor: Conjupro Biotherapeutics, Inc. | N=75 ➔ 7 | Recruiting ➔ Suspended

Enrollment change • Metastases • Trial suspension • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL) (ASH 2022) - P1/2 | "2010]CPO107 is a bispecific fusion protein based off the anti-CD20 ofatumumab antibody with one Fab fragment being replaced with a SIRPα domain, which natively binds CD47...The monoclonal antibody Magrolimab (Hu5F9-G4) in combination with rituximab induced a high rate of tolerable and durable complete responses in heavily pretreated patients (pts) with rituximab-refractory DLBCL and FL [Chao et al...Upon reaching the MTD or RP2D, Part B of the study will enroll approximately 15 pts with CD20+ NHL to explore preliminary efficacy. The study has been registered on ClinicalTrials.gov (NCT04853329)."

Clinical • IO biomarker • P1/2 data • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD47 • SIRPA

CPO107, A Novel CD20-Dependent CD47-Targeting Bispecific Fusion Protein for Advanced CD20-Positive Non-Hodgkins Lymphoma (PPLC 2022) - "In some models, CPO107 at 3.3 mg/kg had comparable activities as rituximab or ofatumumab at 30 mg/kg and CPO107 was active in a rituximab-resistant DLBCL model...In contrast with monospecific CD47-targetig agents (e.g. Hu5F9-G4), CPO107 showed low affinity to red blood cells or platelets...The differentiating mechanism of action of CPO107 as demonstrated in nonclinical studies support the initiation of a Phase 1/2 multicenter dose escalation and dose expansion clinical study in relapsed/refractory NHL patients, which is currently ongoing in the United States."

Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov) - P1/2 | N=75 | Recruiting | Sponsor: Conjupro Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20

CSPC (01093): JMT601 (CPO107) for the treatment of adult relapsed or refractory diffuse large B-cell lymphoma was granted Fast Track designation by the FDA [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, CSPC (01093) announced that the first-in-class drug JMT601 (CPO107) developed by CSPC for the treatment of adult relapsed or refractory diffuse large B-cell lymphoma has been approved by the U.S. Food and Drug Administration ('FDA') Grants Express Entry status. According to the announcement, JMT601 (CPO107) is the world's first bispecific SIRPα fusion protein with synergistic targeting binding effect that has entered clinical development."

IND • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov) - P1/2; N=75; Not yet recruiting; Sponsor: Conjupro Biotherapeutics, Inc.; Initiation date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Aug 2024 ➔ Nov 2024

Clinical • Trial initiation date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov) - P1/2; N=75; Not yet recruiting; Sponsor: Conjupro Biotherapeutics, Inc.

New P1/2 trial • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20

CSPC Pharma’s bi-specific SIRPα fusion protein nails IND nod in US (GBI Health) - "China-based CSPC Pharmaceutical Group Limited (01093.HK) picked up an investigational new drug (IND) approval for JMT601, a bi-specific SIRPα fusion protein, from the US FDA. The targeted indication is advanced non-Hodgkin's lymphoma (nHL)."

IND • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology